A phase II randomized, placebo-controlled trial evaluating nintedanib versus placebo as prophylaxis against radiation pneumonitis in patients with unresectable non-small cell lung cancer (NSCLC ) undergoing chemoradiation therapy (CRT): A National Comprehe
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: TPS8572-TPS8572
10.1200/jco.2016.34.15_suppl.tps8572